U.S. to send more than $100 million in COVID supplies to India
Reuters
Published Apr 28, 2021 11:30PM ET
WASHINGTON (Reuters) -The United States is sending supplies worth more than $100 million to India to help it fight a surge of COVID-19 cases, the White House said in a statement on Wednesday.
The supplies, which will begin arriving on Thursday and continue into next week, include 1,000 oxygen cylinders, 15 million N95 masks and 1 million rapid diagnostic tests, the statement said.
The United States also has redirected its own order of AstraZeneca (NASDAQ:AZN) manufacturing supplies to India, which will allow it to make over 20 million doses of COVID-19 vaccine, according to the White House.
"Just as India sent assistance to the United States when our hospitals were strained early in the pandemic, the United States is determined to help India in its time of need," the White House said in a fact sheet outlining the aid.
India's death toll from the coronavirus pandemic surged past 200,000 on Wednesday, worsened by shortages of hospital beds and medical oxygen. The last 24 hours brought 360,960 new cases for the world's largest single-day total, taking India's tally of infections to nearly 18 million.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.